Introduction

Name

• Maropitant citrate.

Class of drug

• Anti-emetic.
• Neurokinin (NK1) receptor antagonist.

Description

Chemical name

• (2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine citrate monohydrate.

Molecular formula

• C32H40N20C6H807H20

Molecular weight

• 678.81

Physical properties

• Peach-colored oval tablets (16, 24, 60 and 160 mg of maropitant as maropitant citrate per tablet).
• Injectable solution (10 mg maropitant, 63 mg sulphobutylether-beta-cyclodextrin, 3.3 mg meta-cresol and water).

Storage requirements

• Store at controlled room temperature (20-25°C; 68-77°F) with excursions between 15-30°C (59-86°F).
• Use vial of injectable solution within 28 days of first vial puncture.

Uses

Indications

• Prevention of emesis   Vomiting  .
• Prevention of emesis associated with motion sickness in dogs.

Administration

Pharmacokinetics

Precautions

Interactions

with other drugs

• Use with caution with other protein bound drugs. The concomitant use of Cerenia® with other protein bound drugs such as NSAIDs, cardiac, anticonvulsant and behavioral medications has not been evaluated.

Publications

Refereed papers

• Recent references from PubMed and VetMedResource.
• Hickman M A et al (2008) Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther 31 (3), 220-229 PubMed.
• Benchaoui H A, Siedek E M, de la Puente-Redondo V A, Tilt N, Rowan T G & Clemence R G (2007) Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs. Vet Rec 161, 444-447 PubMed.
• Benchaoui H A, Cox S R, Schneider R P, Boucher J F & Clemence R G (2007) The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor anatagonist, in dogs. J Vet Pharmacol Ther 30 (4), 336-344 PubMed.
• de la Puente-Redondo V A, Siedek E M, Benchaoui H A, Tilt N, Rowan T G & Clemence R G (2007) The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe. JSAP 48 (2), 93-98 PubMed.
• de la Puente-Redondo V A, Tilt N, Rowan T G & Clemence R G (2007) Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am J Vet Res 68 (1), 48-56 PubMed.

Other sources of information

• Zoetis: www.zoetisus.com.
• www.cerenia.com/